Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GTC Biotherapeutics and LFB Biotechnologies have agreed to include GTC's recombinant human alpha-1 antitrypsin program in their strategic collaboration for the development of selected recombinant plasma proteins and monoclonal antibodies.
Subscribe to our email newsletter
In accordance with the existing collaboration agreement, LFB will be providing additional funding to support GTC’s work in the recombinant human alpha-1 antitrypsin program for 2008.
In addition to the recombinant alpha-1 antitrypsin program, the GTC/LFB Biotechnologies collaboration includes recombinant factor VIIa, recombinant factor IX, and a monoclonal antibody to CD20. The factor VIIa and factor IX programs are targeted to the treatment of bleeding in hemophilia. The monoclonal antibody to CD20 is targeted at the treatment of B-cell non-Hodgkin’s lymphoma, B-cell leukemia and rheumatoid arthritis.
Geoffrey Cox, GTC’s chairman and CEO, said: “Together with LFB Biotechnologies, we are developing a broad portfolio of recombinant plasma proteins with significant market opportunities which are uniquely supported by our production technology.”